Vaccinex Quote - VCNX

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

3.87

Bid

3.70

Ask

4.10

Volume

36,594

3.67 Day's Range 4.096

1.39 52 Week Range 13.02

Market Cap

10.061M

Previous Close

4.005

Open

4.00

Last Trade

4.06

Last Trade Time

Financial Volume

US$ 141,102

VWAP

3.8559

Average Volume (3m)

113,809

Shares Outstanding

2,599,728

Dividend Yield

PE Ratio

-0.47

Earnings Per Share (EPS)

-7.79

Revenue

570k

Net Profit

-20.25M

Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's product pipeline... Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's product pipeline includes pepinemab (VX15), which targets Huntington's Disease (HD) and non-small cell lung cancer (NSCLC) and also neurodegenerative disorders; VX5 Autoimmune for the treatment of MS and potentially for other autoimmune disorder; and others. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.vaccinex.com

Headquarters

Dover, Delaware, USA

Founded

Vaccinex Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VCNX. The last closing price for Vaccinex was US$4.01. Over the last year, Vaccinex shares have traded in a share price range of US$ 1.39 to US$ 13.02.

Vaccinex currently has 2,599,728 shares outstanding. The market capitalization of Vaccinex is US$10.41 million. Vaccinex has a price to earnings ratio (PE ratio) of -0.47.

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Actively Exploring Partnership for Alzheimer’s DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

ROCHESTER, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

ROCHESTER, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain

ROCHESTER, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.2	5.44959128065	3.67	4.3019	3.5	49846	3.95987467	CS
4	0.22	6.02739726027	3.65	4.73	3.04	68275	3.87320735	CS
12	-0.64	-14.1906873614	4.51	5.01	1.39	113809	3.12768596	CS
26	-2.93	-43.0882352941	6.8	8.9	1.39	91904	4.32050867	CS
52	-4.1352	-51.6564233248	8.0052	13.02	1.39	72699	6.10947434	CS
156	-306.93	-98.7548262548	310.8	478.8	1.39	288188	149.23815566	CS
260	-1176.33	-99.6720894764	1180.2	2568.3	1.39	582576	673.77539261	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WKEYWISeKey International Holdings AG	US$ 7.84 (139.02%)	75.53M
IPHAInnate Pharma SA	US$ 3.00 (93.55%)	13.59M
AVLDirexion Daily AVGO Bull 2X Shares	US$ 33.67 (48.92%)	658.55k
LOOPLoop Industries Inc	US$ 1.8092 (47.09%)	82.56M
AVGXDefiance Daily Target 2X Long AVGO ETF	US$ 31.49 (46.67%)	3.55M
RPTXRepare Therapeutics Inc	US$ 1.765 (-55.54%)	4.7M
INOInovio Pharmaceuticals Inc New	US$ 2.31 (-38.56%)	9.86M
XXII22nd Century Group Inc	US$ 0.048 (-34.69%)	42.23M
FLGCFlora Growth Corporation	US$ 1.30 (-34.34%)	4.14M
WTOUTime Limited	US$ 0.281 (-32.74%)	3.79M
NVDANVIDIA Corporation	US$ 134.25 (-2.25%)	231.23M
SOUNSoundHound AI Inc	US$ 16.905 (23.66%)	159.56M
TRUGTruGolf Holdings Inc	US$ 0.6794 (30.93%)	141.89M
RGTIRigetti Computing Inc	US$ 7.155 (19.85%)	124.45M
AVGOBroadcom Inc	US$ 224.80 (24.43%)	121.33M